TEMPUS TECHNOLOGY COMPANY
Eric Lefkofsky is the founder and Chief Executive Officer of Tempus. Founded in 2015, this technology company not only aggregates clinical information, but it also offers genetic testing. It has three primary business lines. It has genomic tests that physicians can have access to, with its most popular one being one that looks for more than six hundred genes linked with cancer. It also has organized clinical data that has been sourced from its partnerships with medical centres and healthcare systems. Actually, Tempus boasts of having one of the largest clinical and molecular data collection.
Tempus initially dealt with cancer patients. However, due to the recent Corona Virus pandemic, the company has joined the fight against the disease. Back in April, it offered a PCR test for the disease some of its many laboratories. At the moment, the company is targeting a testing capacity of ten thousand tests in a day. It also rolled out a research project that will collect COVID19 patients’ data while looking for patterns that can help in patient treatment as well as drug discovery. As Lefkofsky stated, the real world COVID19 evidence will improve the health sector since physicians will now be able to differentiate and separate patients according to risk.
Tempus’ initiative also includes aggregating data for fifty thousand COVID19 positive patients. The data will be studied to reveal the genetic characteristics that lead to some specific outcomes. It will also help when coming up with treatment practices.